NCT07193511 2026-04-16
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
Clinical Trials
142 trialsNCT02908906 2026-04-13
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT04799054 2026-04-13
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma A/S
Phase 1/2 Terminated
NCT04802759 2026-04-13
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05120596 2026-04-13
First in Human Study of T3P-Y058-739 (T3P)
T3 Pharmaceuticals AG
Phase 1/2 Recruiting
NCT06941272 2026-04-13
MK-9999-01C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07335497 2026-04-13
ASCEND
Crescent Biopharma, Inc.
Phase 1/2 Recruiting
NCT05975073 2026-04-07
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Amgen
Phase 1/2 Active not recruiting
NCT01968109 2026-04-06
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT06238687 2026-04-06
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
Tasly Pharmaceutical Group Co., Ltd
Phase 1/2 Completed
NCT07510828 2026-04-06
PRISM-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT07276373 2026-04-03
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Corcept Therapeutics
Phase 1/2 Recruiting
NCT05516914 2026-04-01
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT07213817 2026-04-01
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Ipsen
Phase 1/2 Recruiting
NCT07213830 2026-03-31
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Ipsen
Phase 1/2 Recruiting
NCT07498725 2026-03-27
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors
LARKSPUR BIOSCIENCES, INC.
Phase 1/2 Not yet recruiting
NCT06014658 2026-03-02
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
MBrace Therapeutics
Phase 1/2 Recruiting
NCT06056791 2026-02-27
CaRe
Inmune Bio, Inc.
Phase 1/2 Completed
NCT06818643 2026-02-19
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04078295 2026-02-10
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
NCT06634849 2026-02-10
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
Pathios Therapeutics Pty Ltd
Phase 1/2 Recruiting
NCT03260023 2026-02-05
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
Transgene
Phase 1/2 Active not recruiting
NCT06077877 2026-02-02
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT04260529 2026-01-29
CICILIA
Cytovation AS
Phase 1/2 Completed
NCT03872778 2026-01-28
NeoRay
Advanced Accelerator Applications
Phase 1/2 Completed
NCT04145622 2026-01-28
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Daiichi Sankyo
Phase 1/2 Recruiting
NCT06840119 2026-01-28
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Immunocore Ltd
Phase 1/2 Recruiting
NCT07112222 2026-01-26
A Study of LM-350 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
Phase 1/2 Recruiting
NCT07073534 2026-01-22
Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT03096093 2026-01-20
Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Cancer Vaccines Limited
Phase 1/2 Active not recruiting
NCT05450562 2026-01-14
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
Sanofi
Phase 1/2 Terminated
NCT05875168 2026-01-12
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Daiichi Sankyo
Phase 1/2 Recruiting
NCT07197827 2025-12-24
A Study of YL242 in Subjects With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT05731271 2025-12-17
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1/2 Active not recruiting
NCT04009681 2025-12-15
HAMMER
Synthorx, Inc, a Sanofi company
Phase 1/2 Terminated
NCT05383170 2025-11-28
Catalyst
Cytovation AS
Phase 1/2 Completed
NCT06184035 2025-11-20
Tumorad
Spago Nanomedical AB
Phase 1/2 Recruiting
NCT03363893 2025-11-12
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
Carrick Therapeutics Limited
Phase 1/2 Completed
NCT03656718 2025-11-12
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05384626 2025-10-30
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Nuvalent Inc.
Phase 1/2 Recruiting
NCT03480646 2025-10-29
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT05118789 2025-10-24
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Nuvalent Inc.
Phase 1/2 Recruiting
NCT02959437 2025-10-21
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
Phase 1/2 Terminated
NCT05898399 2025-10-15
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
Artios Pharma Ltd
Phase 1/2 Active not recruiting
NCT06796907 2025-10-14
BEHOLD-2
GlaxoSmithKline
Phase 1/2 Recruiting
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04701281 2025-09-18
SYS-CAPLIOX
AllVascular
Phase 1/2 Terminated
NCT06193902 2025-09-03
AERIAL
Leucid Bio
Phase 1/2 Recruiting
NCT05220098 2025-08-29
First-in-Human Study of TAK-280 in Participants With Solid Tumors
Takeda
Phase 1/2 Terminated
NCT05394103 2025-08-17
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Qurient Co., Ltd.
Phase 1/2 Recruiting